Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer

IF 4.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Gynecologic oncology Pub Date : 2025-03-15 DOI:10.1016/j.ygyno.2025.03.016
Giuseppe Caruso , Amanika Kumar , Carrie L. Langstraat , Michaela E. McGree , Angela J. Fought , Shariska Harrington , Dimitrios Nasioudis , Giovanni D. Aletti , Nicoletta Colombo , Robert L. Giuntoli , William Cliby
{"title":"Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer","authors":"Giuseppe Caruso ,&nbsp;Amanika Kumar ,&nbsp;Carrie L. Langstraat ,&nbsp;Michaela E. McGree ,&nbsp;Angela J. Fought ,&nbsp;Shariska Harrington ,&nbsp;Dimitrios Nasioudis ,&nbsp;Giovanni D. Aletti ,&nbsp;Nicoletta Colombo ,&nbsp;Robert L. Giuntoli ,&nbsp;William Cliby","doi":"10.1016/j.ygyno.2025.03.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Textbook Oncologic Outcome (TOO) is a composite measure that strongly predicts survival after surgery for advanced epithelial ovarian cancer (AEOC), regardless of approach: primary (PDS) or interval debulking surgery (IDS). We aimed to identify risk factors associated with failure to achieve TOO and to receive standard treatment (surgery and chemotherapy) for AEOC.</div></div><div><h3>Methods</h3><div>Patients diagnosed with AEOC between 2008 and 2019 were identified using the National Cancer Database. TOO was defined as achieving complete cytoreduction, hospital stay &lt;10 days, no 30-day readmission, adjuvant chemotherapy initiation &lt;42 days, and 90-day survival. Logistic regression models were used to identify factors associated with TOO and receipt of standard treatment.</div></div><div><h3>Results</h3><div>Among 58,635 AEOC patients, 49% received standard treatment. Of the 21,657 patients who underwent surgery, 51.4% received PDS and 48.6% IDS. For PDS multivariable analysis, factors associated with lower likelihood to achieve TOO included age &gt;75 years (vs &lt;60; OR 0.47, 95% CI 0.38–0.58), Black race (vs White; OR 0.73, 95% CI 0.59–0.90), government insurance (vs private; OR 0.82, 95% CI 0.73–0.92), high surgical complexity (vs low; OR 0.62, 95% CI 0.56–0.68), and median surgical volume ≤5 cases/year (vs ≥20; OR 0.75, 95% CI 0.63–0.89). For IDS, similar associations were observed for government insurance (OR 0.87, 95% CI, 0.80–0.96), high surgical complexity (OR 0.61, 95% CI 0.55–0.66), and median surgical volume ≤5 cases/year (OR 0.60, 95% CI 0.52–0.70).</div></div><div><h3>Conclusions</h3><div>Several factors are associated with lower likelihood of achieving TOO after treatment for AEOC. Some of these factors (age, race, payor type) reflect disparities in care; others (facility volume, surgical complexity) highlight the need for referral to high-volume centers for initial treatment planning.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"195 ","pages":"Pages 106-114"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S009082582500085X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Textbook Oncologic Outcome (TOO) is a composite measure that strongly predicts survival after surgery for advanced epithelial ovarian cancer (AEOC), regardless of approach: primary (PDS) or interval debulking surgery (IDS). We aimed to identify risk factors associated with failure to achieve TOO and to receive standard treatment (surgery and chemotherapy) for AEOC.

Methods

Patients diagnosed with AEOC between 2008 and 2019 were identified using the National Cancer Database. TOO was defined as achieving complete cytoreduction, hospital stay <10 days, no 30-day readmission, adjuvant chemotherapy initiation <42 days, and 90-day survival. Logistic regression models were used to identify factors associated with TOO and receipt of standard treatment.

Results

Among 58,635 AEOC patients, 49% received standard treatment. Of the 21,657 patients who underwent surgery, 51.4% received PDS and 48.6% IDS. For PDS multivariable analysis, factors associated with lower likelihood to achieve TOO included age >75 years (vs <60; OR 0.47, 95% CI 0.38–0.58), Black race (vs White; OR 0.73, 95% CI 0.59–0.90), government insurance (vs private; OR 0.82, 95% CI 0.73–0.92), high surgical complexity (vs low; OR 0.62, 95% CI 0.56–0.68), and median surgical volume ≤5 cases/year (vs ≥20; OR 0.75, 95% CI 0.63–0.89). For IDS, similar associations were observed for government insurance (OR 0.87, 95% CI, 0.80–0.96), high surgical complexity (OR 0.61, 95% CI 0.55–0.66), and median surgical volume ≤5 cases/year (OR 0.60, 95% CI 0.52–0.70).

Conclusions

Several factors are associated with lower likelihood of achieving TOO after treatment for AEOC. Some of these factors (age, race, payor type) reflect disparities in care; others (facility volume, surgical complexity) highlight the need for referral to high-volume centers for initial treatment planning.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
晚期卵巢癌患者在获得教科书规定的肿瘤治疗结果方面存在的种族/族裔、社会经济和医疗服务差异
目标肿瘤学结局(TOO)是一项综合指标,可有力预测晚期上皮性卵巢癌(AEOC)术后的生存率,无论采用何种方法:初治(PDS)或间期剥除手术(IDS)。我们旨在确定与未能达到TOO和未能接受AEOC标准治疗(手术和化疗)相关的风险因素。方法利用国家癌症数据库对2008年至2019年间诊断为AEOC的患者进行鉴定。TOO定义为达到完全细胞减灭术、住院10天、无30天再入院、辅助化疗开始42天和90天生存率。结果在 58635 名 AEOC 患者中,49% 接受了标准治疗。在接受手术的 21657 名患者中,51.4% 接受了 PDS,48.6% 接受了 IDS。在 PDS 多变量分析中,与实现 TOO 的可能性较低相关的因素包括年龄 >75 岁(vs <60;OR 0.47,95% CI 0.38-0.58)、黑人种族(vs 白人;OR 0.73,95% CI 0.59-0.90)、政府保险(vs 私人保险;OR 0.73,95% CI 0.59-0.90)、手术时间(vs IDS)、术中出血量(vs IDS)、术后出血量(vs IDS)。90)、政府保险(vs 私人保险;OR 0.82,95% CI 0.73-0.92)、手术复杂程度高(vs 低;OR 0.62,95% CI 0.56-0.68)、中位手术量≤5 例/年(vs ≥20;OR 0.75,95% CI 0.63-0.89)。对于 IDS,政府保险(OR 0.87,95% CI,0.80-0.96)、高手术复杂性(OR 0.61,95% CI 0.55-0.66)和中位手术量≤5 例/年(OR 0.60,95% CI 0.52-0.70)也存在类似的关联。其中一些因素(年龄、种族、付款人类型)反映了护理方面的差异;另一些因素(设施数量、手术复杂性)则强调了转诊到高容量中心进行初始治疗规划的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Gynecologic oncology
Gynecologic oncology 医学-妇产科学
CiteScore
8.60
自引率
6.40%
发文量
1062
审稿时长
37 days
期刊介绍: Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy
期刊最新文献
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therapy. Distribution and concordance of HER2 scores in endometrial and ovarian cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1